glp-1 and parkinson's Repurposing Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine The glucagon-like peptide 1 (GLP)

From A-listers on the red carpet to reality TV stars spilling the tea, its clear these weight-loss drugs are having a moment

however, a higher incidence of serious adverse cardiac events (including sustained ventricular tachycardia, atrial fibrillation requiring intervention, and worsening ischemic heart disease) was reported in the liraglutide group compared with placebo (10% vs

The rapid urbanization, changing dietary habits, sedentary lifestyles, and an aging population contribute to the growing incidence of type 2 diabetes

doi: 10.1016/S2213-2600(20)30105-3

(2025) 17:e84944

As of 2025, its still in phase-3 clinical trials by Eli Lilly